Introduction
============

Hepatocellular carcinoma (HCC) is claimed to be the third commonest cause of cancer-associated mortality across the world for its rapid recurrence and metastasis. And HCC is commonly diagnosed in most countries with a high incidence of viral hepatitis.[@b1-ott-10-847] HCC takes up 85%--90% of primary liver cancers with 500,000 new cases as well as 250,000 deaths of HCC all over the world every year.[@b2-ott-10-847] The main reasons for the high mortality rate of HCC patients are ascribed to the lack of effective treatments and the increasing resistance to conventional radiotherapy and chemotherapy.[@b3-ott-10-847] In recent years, improved data of signaling pathways modulating the growth and progression of HCC have resulted in the identification of several new molecular targets. At present, several studies proposed that one of the most promising molecular signaling pathways guiding HCC treatment is the hepatocyte growth factor (HGF)/c-Met signaling.[@b4-ott-10-847],[@b5-ott-10-847]

HGF was first discovered as a factor inducing hepatocyte proliferation, characterized as a motility factor for epithelial cells.[@b6-ott-10-847] Cellular mesenchymal to epithelial transition factor (c-Met), as a high-affinity tyrosine kinase receptor of HGF, can be mediated by HGF. Both HGF and c-Met play an important role in the tumor invasion and metastasis.[@b7-ott-10-847] Increasing expressions of HGF and c-Met in circulating tumor cells reveal a correlation with the progression and metastasis of HCC.[@b8-ott-10-847] The signal triggered by the binding of HGF to c-Met is shown to be one of the leading stimuli during the G1-S development and progression in hepatocytes.[@b2-ott-10-847] Interestingly, HGF/c-Met signaling pathway is crucial for normal embryonic development along with adult tissue reparation in mammal animals, with a certain level in human normal tissue.[@b4-ott-10-847] However, improper amplification of the *c-Met* gene and activation of HGF/c-Met signaling, along with eventually elevated protein expression and constitutive kinase activation, may result in growth, invasion, migration, and tumorigenesis.[@b9-ott-10-847]

Recently, the technology of contrast-enhanced ultra-sonography (CEUS) has been widely applied for the differential diagnosis of metastasis and survival of many human cancers, including breast cancer, colorectal cancer, gastric cancer, pancreatic cancer, and liver cancer.[@b10-ott-10-847]--[@b14-ott-10-847] CEUS is a typical nontraumatic examination method providing blood perfusion parameters and enhancing the accuracy in detecting angiogenesis and neovessels in livers.[@b14-ott-10-847] CEUS is able to show the characteristics of liver tumors accurately and clearly, as well as the perfusion differences between residual carcinoma and necrotic tissue after ablation.[@b15-ott-10-847] Also, CEUS can offer details of tumor necrosis subsequent of ultrasound-guided local ablation more sensitively, which may deliver prompt supplementary treatment and better efficacy.[@b16-ott-10-847] Based on previous studies, the objective of this study is to investigate the correlations of quantitative parameters of CEUS and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with HCC.

Materials and methods
=====================

All subjects provided written informed consent. The collection and application of sample tissue followed ethical guidelines. This study was approved by Ethics Committee of The Hospital of Xi'an Jiao Tong University.

Subjects
--------

A total of 118 patients pathologically diagnosed as HCC from January 2010 to October 2010 in The Hospital of Xi'an Jiao Tong University were included in the follow-up visit. The follow-up and survival data of eligible subjects were complete. All patients were aged between 20 and 76 years, with a median age of 54 years. The clinical information was listed in [Table 1](#t1-ott-10-847){ref-type="table"}. The HCC tissues and adjacent normal tissues (over 5 cm distant from cancer tissue) were obtained and reserved in liquid nitrogen.

CEUS
----

After fasting for 12 h, the patients were examined with iU22 ultrasonic inspection instrument (Royal Philips electronics NV, Eindhoven, the Netherlands; L9-3 wideband probe; pulse inversion harmonic contrast imaging; mechanical index at 0.07). By applying Color Doppler, the strongest flow signal area was frozen and stored as images. Intravenous bolus injection of 0.02 mL/kg fluorocarbon developed by Nanfang Hospital was injected. After the injection, an observation by CEUS lasted for at least 3 min. The real-time dynamic video of the CEUS in the whole process was recorded and stored. The patients were inquired of allergic history. No allergic reaction occurred in the experiment.

According to the blood flow pattern and amount and distribution presented by Doppler, the blood flow signal was scaled as follows: Grade 0 refers to no blood signal in the tissue and its surrounding; Grade 1 refers to a few punctiform blood flow signals in the lesion and a small quantity of blood flow signals in the tissue that surrounds the lesion; Grade 2 refers to a medium amount of blood flow in the tissue, along with a main vessel stretching branches from surrounding to center; Grade 3 refers to abundant blood flow with over 2 main vessels stretching into lesion tissues or being connected with each other. The microvessel image was analyzed with Qlab software (Qlab 9.0; Philips Medical System, Andover, MA, USA) for observing the trace of microbubble in the microvessel. The targeted area of abundant blood vessel was sampled for 3 times and then analyzed to obtain blood perfusion time--intensity curve, time to peak (TTP), peak intensity (PI), area under the curve (AUC), and washout time (WOT).

Immunohistochemistry
--------------------

The HCC tissues and adjacent nontumor tissues were obtained and fixed with 4% formalin. After gradient alcohol dehydration, the tissues were embedded with paraffin and then sliced to serial tissue sections of 5-μm thick. After routine dewaxing and antigen reparation, the tissues were sealed with blocking buffer. Then the slices were added with HGF or c-Met antibody (dilution at 1:500, 100 μL/slice; Abcam Co., Cambridge, MA, USA) and incubated at 4°C overnight. After washing by phosphate buffer solution Tween-20 (PBST), the biotinylated secondary antibody (dilution at 1:500; Abcam Co.) was added and the tissues were incubated at 37°C for 2 h. Avidin-Biotin-Enzyme Complex (ABC) were added for incubation at 37°C for 1 h. After diaminobenzidine (DAB) color reaction, the slices were blocked, observed, and photographed under optical microscope (Olympus, Southborough, MA, USA). The immunohistochemistry kit was purchased from Roche (Hoffmann-La Roche Ltd, Mannheim, Germany). Under the same light intensity, the HGF and c-Met in HCC tissues and adjacent nontumor tissues were examined, with a random selection of 4 fields assigned to each slice. The percentage of positive cells displayed in the immunohistochemical staining under the high power lens of ×400 was counted as an index. The positive rate = the number of positive cells/the number of cells in the fields ×100%.

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

The RNA was extracted with TRIzol (Invitrogen Biotechnology Co., Shanghai, People's Republic of China) and examined of its concentration and purity with NanoDrop2000 (Thermo Fisher Scientific Inc., Waltham, MA, USA). The extracted RNA was reserved at −80°C for further usage. According to the published gene sequence by Genebank database, PCR primer sequence ([Table 2](#t2-ott-10-847){ref-type="table"}) was designed with Primer 5.0 software (Shanghai GenePharm Co., Ltd., Shanghai, People's Republic of China). The PCR system was 12.5 μL of SYBR Premix Ex Taq II (Takara Bio Inc., Dalian, People's Republic of China); 1 μL of forward and 1 μL of reverse primers; 2 μL of DNA template; 8.5 μL of sterile water; internal reference gene, β-actin. The PCR condition was initial denaturation at 95°C for 30 s; denaturation at 95°C for 5 s, annealing at 51°C for 25 s, and elongation at 65°C for 10 s, 40 cycles of these three procedures in total. The PCR results were evaluated by dissolution curve. The threshold cycle (CT) was obtained at the inflection point of amplification curve. ΔCt = CT (target gene) − CT (β-actin), ΔΔCt = ΔCt (HCC tissue) − ΔCt (adjacent tissue). The relative expression of target gene was calculated as 2^−ΔΔCt^.[@b17-ott-10-847]

CD34 immunohistochemistry
-------------------------

The microvessel density (MVD) was detected through immunohistochemistry (the immunohistochemistry kit was purchased from Hoffmann-La Roche Ltd) using CD34 monoclonal antibody. The slices of HCC tissues and adjacent nontumor tissues were taken for routine dewaxing, antigen retrieval, and sealing. After adding CD34 monoclonal antibody (dilution at 1:100; Abcam Co.) of 100 μL into each slice, the tissues were incubated at 4°C overnight. Then, the slices were washed with PBST and added with the biotin-labelled secondary antibody (dilution at 1:500; Abcam Co.) for a 2-hour incubation at 37°C. The streptavidin avidin biotin complex was added, and the slices were incubated at 37°C for 1 h. After DAB color reaction, hematoxylin was applied for a 2-min counterstaining. And the slices were sealed with neutral resin and observed under optical microscope (Olympus) in a low power (×100) for selection of areas with most new vessels. Cell counting was performed in a high power (×400). Each group was assigned with 6 fields, the average of which was calculated as the MVD. The endothelial cells or cell clusters that presented brown color in immunohistochemistry staining and displayed a distinct border with adjacent microvessels and tumor cells in tumor tissues were all new tumor vessels.

Follow-up
---------

After the collection of basic information of patients, the follow-up was conducted for all patients, who underwent tumor resection. The clinical information and postoperative symptoms were recorded and completed. The reexaminations were performed for these patients at 1 week, 1 month, 3 months, and every 3 months after the surgery. At the same time, the CEUS was applied to detect the liver function and the prognosis of patients. The follow-up visit spanned for 37 months on average. The survival time for the patient was from the first day in hospital to the date of death. Whether the patient died of other diseases, accident, or was alive at the end of the follow-up visit, the censored value was regarded as his survival time. The follow-up visit started from the end of the surgery and lasted until November 2015. The survival time should be monthly, and the time of disease-free survival (DFS) was counted until a tumor recurrence or metastatic lesions was observed with imageological examination, or until the death of patient apart from the tumor recurrence. The recurrence was first defined as the intrahepatic manifestation of HCC or obvious extrahepatic metastasis with imageological examination. The 1-, 3-, and 5-year DFS rates were recorded. And the correlations of clinical characteristics and contrast parameters with prognosis of patients were analyzed.

A nude mice model of HCC
------------------------

The human HCC cell line HepG2 was purchased from the cell bank of Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, People's Republic of China). The SU11274, a c-Met kinase inhibitor, was from Sigma-Aldrich Chemical Company (St Louis, MO, USA). The BALB/C (n/n) male nude 3-week-old mice were bought from Laboratory Animal Center of Chinese Academy of Sciences. The mice were stored in feeding boxes of polymethyl methacrylate in an ultraclean laminar-flow cabinet and fed in the conditions of a constant temperature, constant humidity, and specific pathogen free. Free access to sterile water and food was provided for these mice. After trypsinization of HepG2 cells at logarithmic phase of growth, the concentration of HepG2 cells was adjusted to 1×10^7^ cells per mL with phosphate-buffered saline. Each mouse was given subcutaneous injection with 0.5 mL prepared solution. After \~10 days, the average volume of tumor in mice could be 100 mm^3^, mice with tumor volume much larger or smaller than which were excluded. Then, 30 HCC mice of the rest were randomly selected and divided into three groups with 10 mice in each group, including experimental group (injection of SU11274, a c-Met inhibitor, 0.09 mg/kg), negative control group (injection of normal saline), and blank group (no injection). The administration of intraperitoneal injection lasted for 30 days, once daily. The growth of HCC in mice was observed each day since the first day of injection. The width and length of the tumor in HCC mice were measured and the tumor volume was calculated using the formula *V* = ½*ab*^2^ (*a*, length; *b*, width). Finally, a tumor growth curve was obtained.

On the 24th hour after the last administration, the CEUS examination was applied in HCC mice. The HCC mice were fixed after intraperitoneal anesthesia with certain 10% chloral hydrate on the basis of their weight (0.1 mL/20 g). The time--intensity curve was obtained with the enhancing region served as a region of interest. The AUC, PI, TTP, and WOT of CEUS were obtained. The HCC mice were killed after CEUS examination, and tumor weights were obtained after complete tumor resection. The inhibition rate of tumor (%) = \[1 − (average weight of tumors)~the\ experiment\ group~/(average weight of tumors)~the\ blank\ group~\]×100%. The MVD of HCC tissues was measured by CD34 immunohistochemistry.

Statistical analysis
--------------------

Data were analyzed with the statistical package for the social sciences (SPSS) version 20.0 (SPSS Inc.; Chicago, IL, USA). *T*-test was applied to analyze the differences between two groups, where continuous data were presented as mean ± standard deviation. Differences among multiple groups were compared by one-way analysis of variance. Categorical data were expressed as ratio and percentage and examined with chi-square test. Univariate survival analysis was based upon Kaplan--Meier analysis, and multivariate survival analysis was performed using Cox proportional hazards model. The level of *P*\<0.05 was considered as significant.

Results
=======

HGF and c-Met protein expressions in HCC and adjacent normal tissues
--------------------------------------------------------------------

The positive expression of HGF was signaled by brown particles in nucleus and cytoplasm and the positive expression of c-Met was implied by brown particles in both cytoplasm and cell membrane. The results of immunochemistry indicated that positive expressions of HGF in the HCC tissues were significantly reduced while positive expressions of c-Met in HCC tissues were elevated in comparison with the adjacent normal tissues ([Figure 1](#f1-ott-10-847){ref-type="fig"}). The PCR detection revealed that HGF mRNA expressions were lower and c-met mRNA expressions were higher in the HCC tissues than these in the adjacent normal tissues, which were consistent with the findings of immunochemistry (all *P*\<0.05).

Comparison of MVD between HCC and adjacent normal tissues
---------------------------------------------------------

The CD34 immunochemistry found no positive expression of CD34 staining in the adjacent normal tissues, while positive expressions of CD34 were abundant in the HCC tissues ([Figure 2A](#f2-ott-10-847){ref-type="fig"}). Additionally, MVD in HCC tissues was significantly higher than that in the adjacent normal tissues ([Figure 2B](#f2-ott-10-847){ref-type="fig"}).

Comparisons of quantitative parameters of CEUS between liver parenchyma and HCC lesions
---------------------------------------------------------------------------------------

The number of blood vessels in HCC lesions was increased in comparison with that in the liver parenchyma. The analysis of the blood perfusion time--intensity curve found that the TTP and WOT of CEUS in the HCC lesions were decreased, while PI and AUC of CEUS in HCC lesions were elevated compared with those in the liver parenchyma (all *P*\<0.05, [Table 3](#t3-ott-10-847){ref-type="table"}).

Correlations of HGF and c-Met protein expressions and MVD with clinicopathological features of HCC patients
-----------------------------------------------------------------------------------------------------------

HGF and c-Met proteins expressions and MVD exhibited no correlation with age, gender, tumor differentiation, tumor number, and vascular invasion (all *P*\>0.05), but evident correlations with TNM stage, tumor size, and vascular invasion of HCC patients (all *P*\>0.05). Besides, HGF and c-Met proteins expressions were also significantly associated with liver cirrhosis, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection of HCC patients (all *P*\<0.05), while MVD was not associated with these of HCC patients (all *P*\>0.05) ([Table 4](#t4-ott-10-847){ref-type="table"}).

Correlations of quantitative parameters of CEUS with clinicopathological features of HCC patients
-------------------------------------------------------------------------------------------------

On the basis of positive expressions of HGF and c-Met protein in HCC tissues, the HCC patients were classified into four groups: the HGF-positive group, the HGF-negative group, the c-Met-positive group, and the c-Met-negative group. And the subgroups of MVD of HCC patients were the high-value group and the low-value group based on the median of MVD (M =48). The data revealed that the patients' age and gender exerted no significant influence on the TTP, PI, AUC, and WOT (all *P*\>0.05), while tumor size, tumor number, vascular invasion, HGF and c-Met protein expressions, and MVD were significantly related to the TTP, PI, AUC, and WOT (all *P*\<0.05, [Table 5](#t5-ott-10-847){ref-type="table"}).

Correlations of HG/c-Met protein expressions, MVD, and quantitative parameters of CEUS with prognosis of HCC patients
---------------------------------------------------------------------------------------------------------------------

According to the median of TTP, PI, AUC, and WOT (22 s, 58.7 dB, 572.8 dB\*s, and 67 s, respectively), each parameter of CEUS of HCC patients was also classified into 2 groups. The univariate survival analysis implied that the patients' age and gender had no significant influence on the survival prognosis and the 1-, 3-, and 5-year DFS rates. Tumor differentiation, TNM stage, tumor size, tumor number, vascular invasion, HGF and c-Met protein expressions, and MVD exerted remarkable influence on the 1-, 3-, and 5-year DFS rates (all *P*\<0.05). Moreover, the preoperative TTP, PI, AUC, and WOT were also associated with the 1-, 3-, and 5-year DFS rates (all *P*\<0.05, [Table 6](#t6-ott-10-847){ref-type="table"}).

The factors related to recurrence of HCC were obtained with the univariate survival analysis, including tumor differentiation, TNM stage, tumor size, tumor number, vascular invasion, HGF and c-Met protein expressions, MVD, and quantitative parameters of CEUS. Further multivariate survival analysis using Cox's proportional hazards model indicated that the recurrence of HCC was significantly correlated with tumor differentiation, TNM stage, tumor size, tumor number, vascular invasion, HGF and c-Met expressions, MVD, and preoperative PI (all *P*\<0.05, [Table 7](#t7-ott-10-847){ref-type="table"}).

Effects of c-Met inhibitor on the growth and MVD of transplanted tumors in nude mice
------------------------------------------------------------------------------------

At each time point after the administration of c-Met inhibitor, the volumes of transplanted tumors in nude mice of the experimental group were smaller than these of the blank and negative control groups (all *P*\<0.05), and no significant difference of tumor volume was observed between the blank group and the negative control group (*P*\>0.05) ([Figure 3A](#f3-ott-10-847){ref-type="fig"}). Thus, SU11274 (a c-Met inhibitor) injection can suppress the growth of transplanted tumors in nude mice. The final tumor weight of the experimental group, the blank group, and the negative control group were 1.05±0.11 g, 1.87±0.15 g, and 1.89±0.18 g, respectively. Compared with the blank and negative control groups, the tumor weight of the experimental group was much lower (both *P*\>0.05), and no significant difference of tumor weight was observed between the blank group and the negative control group (*P*\>0.05) ([Figure 3B](#f3-ott-10-847){ref-type="fig"}). The inhibition rate of tumor of the experimental group (43.73%) indicated that SU11274 can suppress the growth of HCC.

The MVD in the experimental group (29.24±5.36) was much lower than that in the blank group (51.12±9.08) and the negative control group (49.42±8.75) (both *P*\<0.05), while no significant difference of MVD was observed between the blank group and the negative control group (*P*\>0.05) ([Figure 4](#f4-ott-10-847){ref-type="fig"}).

Comparisons of quantitative parameters of CEUS of transplanted tumors in nude mice among the three groups
---------------------------------------------------------------------------------------------------------

Compared with the blank and negative control groups ([Figure 5](#f5-ott-10-847){ref-type="fig"}), the PI and AUC of CEUS in the experimental group were evidently decreased (all *P*\<0.05), and the TTP and WOT of CEUS in the experimental group were evidently raised (all *P*\<0.05). These four parameters showed no significant difference between the blank group and the negative control group (*P*\>0.05).

Discussion
==========

The findings of this study revealed that HGF protein expression was reduced, and c-Met protein expression was elevated in the HCC tissues in comparison with these in the adjacent normal tissues. MVD value in the HCC tissues was significantly higher than that in the adjacent normal tissues. Further analysis reveals that HGF and c-Met expressions and MVD were related to TNM stage, tumor size, and vascular invasion. Moreover, HGF and c-Met protein expressions, MVD, and preoperative PI exerted significant correlations with the prognosis of patients with HCC. Collectively, this study supported that HGF/c-Met signaling pathway combined with CEUS might be related to the clinicopathological features and prognosis of patients with HCC.

Compared with the adjacent normal tissues, the mRNA and protein expressions of HGF were reduced, and mRNA and protein expressions of c-Met level were increased in the HCC tissues, both of which were closely correlated with clinicopathological features and prognosis of HCC patients. The HGF/c-Met signaling pathway is involved in a wide variety of solid tumors and hematopoietic derived malignancies, which plays a crucial role in malignant transformation through promotion of tumor cell migration, invasion, and epithelial to mesenchymal transition. Goyal et al demonstrate that HGF expression is decreased in HCC tissue in comparison with adjacent normal tissue; on the other hand, c-MET transcription is elevated in 30%--100% of cancer tissue relative to adjacent normal tissue.[@b18-ott-10-847] Consistent with this finding, the results of this study indicated lower protein and mRNA expressions of HGF, and higher protein and mRNA expressions of c-Met in HCC tissues than these in the adjacent normal tissues. Furthermore, Liu et al suggest that HGF/c-Met signaling pathway is able to promote cell migration and invasion through Snail activation.[@b4-ott-10-847] Marquardt et al report that overexpression of MET is indicated to be significantly related with vascular invasion, neoangiogenesis, and poor outcome in patients with liver cancer.[@b19-ott-10-847] The present study further proved that the protein expressions of HGF/c-Met were associated with the clinicopathological features of HCC patients such as TNM stage, tumor size, vascular invasion, liver cirrhosis, and HBV and HCV infections. It has been reported that aberrant expression of HGF/c-Met signaling is involved in aggressive liver tumors and may cause poor prognosis.[@b20-ott-10-847] Bozkaya et al identified that the activation of HGF/c-Met signaling is correlated with aggressive phenotype and poor prognosis in HCC.[@b2-ott-10-847] Kondo et al have proposed that c-Met may be a useful predictive marker of recurrence in resected HCC patients.[@b21-ott-10-847] Therefore, it is assumed that HGF/c-Met signaling may play an important role in the recurrence and prognosis of HCC. With univariate survival analysis, the protein expressions of HGF/c-Met were closely related to the DFS rates of HCC; moreover, the tumor differentiation, tumor size, tumor number, TNM stages, and vascular invasion were also associated with the DFS rates of HCC.

Additionally, the study revealed that quantitative parameters of CEUS as well as MVD were also correlated with clinicopathological features and prognosis of HCC patients. Nowadays, quantitative determination of the MVD is a commonly used method for both evaluating angiogenesis in tumor tissues and identifying the biological characteristics and prognosis of patients with HCC.[@b22-ott-10-847] MVD is high in prostate cancer tissues, and an association of high MVD with the prognosis and progression of prostate cancer is observed in the metastases, disease-specific survival as well as stage of disease.[@b23-ott-10-847] The technology of CEUS has been developed to reflect the neovessels in tumors.[@b15-ott-10-847] Different CEUS parameters are correlated with the different proportions between the portal veins and hepatic arteries, together with the different vascular structures in tumors.[@b14-ott-10-847] As main parameters of CEUS, PI and AUC are used to estimate enhancement intensity, and TTP and AUC are associated with enhancement time. PI and AUC of CEUS are applied to evaluate tumor vascularity in ovarian tumors as noninvasive parameters.[@b24-ott-10-847] In compliance with the above points, positive expressions of CD34 were abundant and MVD was high in the HCC tissues. The TTP, PI, AUC, and WOT were significantly associated with tumor size, tumor number, vascular invasion, and MVD. These parameters were also correlated with 1-, 3-, and 5-year DFS rates. PI of CEUS was also demonstrated to be associated with the recurrence of HCC. Additionally, this study first time found that TTP, PI, AUC, and WOT were associated with the HGF and c-Met protein expressions in patients with HCC. Therefore, CEUS might directly reflect the intratumoral HGF and c-Met protein expressions and neovascular generation as well as prognosis of patients with HCC.

To conclude, the present study demonstrated that HGF and c-Met protein expressions and quantitative parameters of CEUS were correlated with the clinicopathological features of HCC patients. Further evidences indicated that HGF and c-Met protein expressions, MVD, and preoperative PI exert significant influence on the prognosis of HCC patients. Collectively, this study supports that quantitative parameters of CEUS and HGF/c-Met signaling pathway-related proteins may be helpful for early diagnosis and prognosis prediction of HCC patients. Nevertheless, the small sample size might have a small influence on the conclusion so that a larger sample size is needed in the future study. And more specific mechanism of this finding should be supplemented later so that strong evidence could be provided for predicting prognosis of patients with HCC.
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![The protein and mRNA expressions of HGF and c-Met expressions in the HCC and adjacent normal tissues (×200). (**A**) The protein expressions of HGF and c-Met in HCC and adjacent normal tissues; (**B**) the HGF mRNA expressions in HCC and adjacent normal tissues; (**C**) the c-Met mRNA expressions in HCC and adjacent normal tissues; \**P*\<0.05 compared with the adjacent normal tissues.\
**Abbreviations:** HGF, hepatocyte growth factor; c-Met, cellular mesenchymal to epithelial transition factor; HCC, hepatocellular carcinoma.](ott-10-847Fig1){#f1-ott-10-847}

![Comparison of microvessel density in the HCC and adjacent normal tissues. (**A**) The CD34 expression in HCC tissues and adjacent normal tissues (×400); (**B**) Comparison of MVD in the HCC and adjacent normal tissues; \*\**P*\<0.01 compared with the adjacent normal tissues.\
**Abbreviations:** MVD, micro-vessel density; HCC, hepatocellular carcinoma.](ott-10-847Fig2){#f2-ott-10-847}

![Effects of c-Met inhibitor on the growth of transplanted tumors in nude mice. (**A**) The growth of transplanted tumors in nude mice of three groups; (**B**) comparison of weights of transplanted tumors in nude mice of three groups; \**P*\<0.05 compared with blank group.\
**Abbreviation:** c-Met, cellular-mesenchymal to epithelial transition factor.](ott-10-847Fig3){#f3-ott-10-847}

![Effects of c-Met inhibitor on MVD of transplanted tumors in nude mice. (**A**) The MVD of transplanted tumors in nude mice of the experimental group, ×400; (**B**) the MVD of transplanted tumors in nude mice of the negative control group, ×400; (**C**) the MVD of transplanted tumors in nude mice of the blank group, ×400; (**D**) comparison of MVD among three groups; \**P*\<0.05 compared with blank group.\
**Abbreviations:** c-Met, cellular-mesenchymal to epithelial transition factor; MVD, microvessel density.](ott-10-847Fig4){#f4-ott-10-847}

![Comparisons of quantitative parameters of CEUS of transplanted tumors in nude mice among three groups. \**P*\<0.05 compared with blank group.\
**Abbreviations:** AUC, area under the curve; CEUS, contrast-enhanced ultrasound; PI, peak intensity; TTP, time to peak; WOT, washout time.](ott-10-847Fig5){#f5-ott-10-847}

###### 

Clinicopathological features of 118 patients with hepatocellular carcinoma

  Feature                                                     Case number
  ----------------------------------------------------------- -------------
  Gender (male/female)                                        75/43
  Smoking history (yes/no)                                    68/50
  Alcohol history (yes/no)                                    79/39
  Tumor differentiation (high/moderate/low differentiation)   46/41/31
  TMN stage (I/II/III/IV)                                     20/21/36/41
  Tumor size (\<3 cm/≥3 cm)                                   56/62
  Tumor number (\<3/≥3)                                       53/65
  Vascular invasion (yes/no)                                  67/51
  Lymphatic invasion (yes/no)                                 71/47
  Liver cirrhosis (yes/no)                                    75/43
  AFP (\<20/≥20 ng/mL)                                        35/83
  HBsAg/HCV (negative/positive)                               87/31
  HBV-DNA (negative/positive)                                 42/76

**Abbreviations:** TNM, tumor, node, and metastasis; AFP, alpha-fetoprotein; HBsAg/HCV, hepatitis B surface antigen/hepatitis C virus; HBV-DNA, hepatitis B virus-DNA.

###### 

The primers for quantitative real-time polymerase chase reaction

  Gene                             Primer sequence (5′--3′)
  -------------------------------- ----------------------------------
  *HGF*                            Forward: GAATGACACTGATGTTCCTTTGG
  Reverse: GGATACTGAGAATCCCAACGC   
  *c-Met*                          Forward: GCAGGTTGTGGTTTCTCG
  Reverse: TGCAGCCCAAGCCATTCA      
  *β-Actin*                        Forward: CGGGAAATCGTGCGTGAC
  Reverse: AGGCAGCTCGTAGCTCTTCT    

###### 

Comparisons of quantitative parameters of CEUS between liver parenchyma and HCC lesions

  Tissues            Time to peak (s)                                        Peak intensity (dB)                                      Area under the curve (dB^\*^s)                               Washout time (s)
  ------------------ ------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------
  HCC lesions        21.81±5.13[\#](#tfn2-ott-10-847){ref-type="table-fn"}   58.70±10.10[\#](#tfn2-ott-10-847){ref-type="table-fn"}   1,162.50±141.20[\#](#tfn2-ott-10-847){ref-type="table-fn"}   32.60±6.40[\#](#tfn2-ott-10-847){ref-type="table-fn"}
  Liver parenchyma   30.22±7.51                                              43.20±8.50                                               572.80±41.70                                                 67.34±11.16

**Note:**

*P*\<0.05 compared with the adjacent normal tissues.

**Abbreviations:** CEUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma.

###### 

Correlations of HGF and c-Met protein expressions and MVD with clinicopathological features of HCC patients

  Feature                 HGF expression (%)   *P*-value   c-Met expression (%)   *P*-value   MVD          *P*-value
  ----------------------- -------------------- ----------- ---------------------- ----------- ------------ -----------
  Age (years)                                  0.938                              0.367                    0.888
   \<50                   32.65                            69.39                              47.49±7.13   
   ≥50                    33.33                            76.81                              47.71±9.09   
  Gender                                       0.192                              0.573                    0.185
   Male                   37.33                            72.00                              48.39±8.42   
   Female                 25.58                            76.74                              46.28±8.00   
  Tumor differentiation                        0.352                              0.239                    0.592
   Low                    22.58                            70.97                              48.94±9.40   
   Moderate               36.59                            82.93                              47.19±7.12   
   High                   36.96                            67.39                              47.12±8.57   
  TNM stage                                    0.025                              0.006                    0.02
   I + II                 46.34                            58.54                              45.19±8.62   
   III + IV               25.97                            81.82                              48.91±7.88   
  Tumor size                                   0.003                              0.027                    0.002
   \<3 cm                 46.43                            64.29                              45.20±8.80   
   ≥3 cm                  20.97                            82.26                              49.81±7.21   
  Tumor number                                 0.56                               0.219                    0.273
   \<3                    35.85                            79.25                              46.69±7.71   
   ≥3                     30.77                            69.23                              48.38±8.74   
  Vascular invasion                            0.042                              0.005                    0.002
   Yes                    25.37                            83.58                              49.66±7.14   
   No                     43.14                            60.78                              44.94±9.01   
  Liver cirrhosis                              0.025                              0.042                    0.157
   Yes                    25.33                                                                            
   No                     46.51                                                                            
  HCV infection                                0.026                              0.046                    0.780
   Positive               16.13                            48.39                              47.51±8.82   
   Negative               39.08                            27.59                              47.94±6.76   
  HBV infection                                0.015                              0.024                    0.596
   Positive               25.00                            40.79                              47.92±8.15   
   Negative               47.62                            19.0                               47.07±8.63   

**Abbreviations:** HGF, hepatocyte growth factor; c-Met, cellular mesenchymal to epithelial transition factor; HCC, hepatocellular carcinoma; TNM, tumor, node, and metastasis; MVD, microvessel density; HCV, hepatitis C virus; HBV, hepatitis B virus.

###### 

Correlations of quantitative parameters of CEUS with clinicopathological features of HCC patients

  Feature                 Time to peak (s)                                        Peak intensity (dB)                                      Area under the curve (dB^\*^s)                            Washout time (s)
  ----------------------- ------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------
  Age (years)                                                                                                                                                                                        
   \<50                   21.71±6.23                                              58.81±10.94                                              576.18±38.77                                              68.33±11.68
   ≥50                    21.88±4.23                                              58.62±9.54                                               570.40±43.78                                              66.63±10.81
  Gender                                                                                                                                                                                             
   Male                   22.04±5.50                                              58.74±9.65                                               573.53±43.25                                              66.40±11.10
   Female                 21.41±4.45                                              58.62±10.95                                              571.52±39.32                                              68.98±11.22
  Tumor differentiation                                                                                                                                                                              
   Low                    21.69±4.82                                              59.42±9.17                                               572.88±44.60                                              66.73±12.76
   Medium                 21.94±4.89                                              57.38±10.45                                              569.88±39.48                                              67.17±10.19
   High                   21.78±5.63                                              59.39±10.47                                              575.35±42.37                                              67.90±11.07
  TNM stage                                                                                                                                                                                          
   I + II                 25.18±4.75                                              56.73±11.11                                              576.65±44.77                                              66.68±12.56
   III + IV               20.02±4.39[\#](#tfn5-ott-10-847){ref-type="table-fn"}   59.75±9.42                                               570.75±40.12                                              67.69±10.41
  Tumor size                                                                                                                                                                                         
   \<3 cm                 23.36±6.04                                              55.02±10.84                                              563.39±45.97                                              70.71±11.18
   ≥3 cm                  20.41±3.65[\#](#tfn5-ott-10-847){ref-type="table-fn"}   62.03±8.13[\#](#tfn5-ott-10-847){ref-type="table-fn"}    583.21±33.84[\#](#tfn5-ott-10-847){ref-type="table-fn"}   63.60±9.97[\#](#tfn5-ott-10-847){ref-type="table-fn"}
  Tumor number                                                                                                                                                                                       
   \<3                    23.30±4.22                                              54.76±9.83                                               561.50±39.94                                              69.93±10.88
   ≥3                     20.60±5.50[\#](#tfn5-ott-10-847){ref-type="table-fn"}   61.92±9.20[\#](#tfn5-ott-10-847){ref-type="table-fn"}    586.65±39.92[\#](#tfn5-ott-10-847){ref-type="table-fn"}   64.15±10.76[\#](#tfn5-ott-10-847){ref-type="table-fn"}
  Vascular invasion                                                                                                                                                                                  
   Yes                    20.41±5.27                                              62.87±9.82                                               595.61±37.39                                              63.57±12.24
   No                     23.65±4.34[\#](#tfn5-ott-10-847){ref-type="table-fn"}   53.22±7.58[\#](#tfn5-ott-10-847){ref-type="table-fn"}    555.44±36.27[\#](#tfn5-ott-10-847){ref-type="table-fn"}   70.21±9.38[\#](#tfn5-ott-10-847){ref-type="table-fn"}
  HGF expression                                                                                                                                                                                     
   Positive               23.18±6.22                                              54.00±8.49                                               567.35±40.86                                              68.90±10.68
   Negative               21.14±4.38[\#](#tfn5-ott-10-847){ref-type="table-fn"}   61.02±10.07[\#](#tfn5-ott-10-847){ref-type="table-fn"}   583.84±41.71[\#](#tfn5-ott-10-847){ref-type="table-fn"}   64.17±11.58[\#](#tfn5-ott-10-847){ref-type="table-fn"}
  c-Met expression                                                                                                                                                                                   
   Positive               20.67±4.44                                              60.41±9.97                                               591.74±37.66                                              65.30±12.03
   Negative               25.01±5.63[\#](#tfn5-ott-10-847){ref-type="table-fn"}   53.89±8.98[\#](#tfn5-ott-10-847){ref-type="table-fn"}    566.05±41.18[\#](#tfn5-ott-10-847){ref-type="table-fn"}   68.06±10.82[\#](#tfn5-ott-10-847){ref-type="table-fn"}
  MVD                                                                                                                                                                                                
   High                   20.04±3.73                                              62.38±9.60                                               584.62±40.13                                              65.36±12.13
   Low                    23.58±5.72[\#](#tfn5-ott-10-847){ref-type="table-fn"}   55.02±9.28[\#](#tfn5-ott-10-847){ref-type="table-fn"}    560.98±40.16[\#](#tfn5-ott-10-847){ref-type="table-fn"}   69.31±9.82[\#](#tfn5-ott-10-847){ref-type="table-fn"}

**Note:**

*P*\<0.05 of comparison within group.

**Abbreviations:** HGF, hepatocyte growth factor; c-Met, cellular mesenchymal to epithelial transition factor; TNM, tumor, node, and metastasis; MVD, microvessel density.

###### 

Univariate survival analysis of risk factors for the prognosis of HCC patients

  Factor                  1-year DFS rate (%)                                3-year DFS rate (%)                                5-year DFS rate (%)
  ----------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  Age (years)                                                                                                                   
   \<50                   71.43                                              59.18                                              40.82
   ≥50                    72.46                                              56.52                                              37.68
  Gender                                                                                                                        
   Male                   76.00                                              60.00                                              41.33
   Female                 65.12                                              53.49                                              34.88
  Tumor differentiation                                                                                                         
   Low                    51.61[\#](#tfn7-ott-10-847){ref-type="table-fn"}   32.26[\#](#tfn7-ott-10-847){ref-type="table-fn"}   12.90[\#](#tfn7-ott-10-847){ref-type="table-fn"}
   Medium                 63.41[\#](#tfn7-ott-10-847){ref-type="table-fn"}   53.66[\#](#tfn7-ott-10-847){ref-type="table-fn"}   34.15[\#](#tfn7-ott-10-847){ref-type="table-fn"}
   High                   93.48                                              78.26                                              60.87
  TNM stage                                                                                                                     
   I + II                 92.68                                              92.68                                              68.29
   III + IV               61.04[\#](#tfn7-ott-10-847){ref-type="table-fn"}   38.96[\#](#tfn7-ott-10-847){ref-type="table-fn"}   23.38[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Tumor size                                                                                                                    
   \<3 cm                 94.64                                              73.21                                              53.57
   ≥3 cm                  51.61[\#](#tfn7-ott-10-847){ref-type="table-fn"}   43.55[\#](#tfn7-ott-10-847){ref-type="table-fn"}   25.81[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Tumor number                                                                                                                  
   \<3                    83.02                                              71.70                                              56.60
   ≥3                     63.08[\#](#tfn7-ott-10-847){ref-type="table-fn"}   46.15[\#](#tfn7-ott-10-847){ref-type="table-fn"}   24.62[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Vascular invasion                                                                                                             
   Yes                    61.19                                              41.79                                              25.37
   No                     86.27[\#](#tfn7-ott-10-847){ref-type="table-fn"}   78.43[\#](#tfn7-ott-10-847){ref-type="table-fn"}   56.86[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  HGF expression                                                                                                                
   Positive               87.18                                              79.49                                              66.67
   Negative               64.56[\#](#tfn7-ott-10-847){ref-type="table-fn"}   46.84[\#](#tfn7-ott-10-847){ref-type="table-fn"}   25.32[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  c-Met expression                                                                                                              
   Positive               66.67                                              50.57                                              33.33
   Negative               87.10[\#](#tfn7-ott-10-847){ref-type="table-fn"}   77.42[\#](#tfn7-ott-10-847){ref-type="table-fn"}   54.84[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  MVD                                                                                                                           
   High                   52.54                                              32.20                                              16.95
   Low                    91.53[\#](#tfn7-ott-10-847){ref-type="table-fn"}   83.05[\#](#tfn7-ott-10-847){ref-type="table-fn"}   61.02[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Time to peak                                                                                                                  
   Short                  61.02                                              44.07                                              23.73
   Long                   83.05[\#](#tfn7-ott-10-847){ref-type="table-fn"}   71.19[\#](#tfn7-ott-10-847){ref-type="table-fn"}   54.24[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Peak intensity                                                                                                                
   Strong                 61.02                                              44.07                                              23.73
   Weak                   83.05[\#](#tfn7-ott-10-847){ref-type="table-fn"}   71.19[\#](#tfn7-ott-10-847){ref-type="table-fn"}   54.24[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Area under the curve                                                                                                          
   Small                  83.05                                              71.19                                              54.24
   Large                  61.02[\#](#tfn7-ott-10-847){ref-type="table-fn"}   44.07[\#](#tfn7-ott-10-847){ref-type="table-fn"}   23.73[\#](#tfn7-ott-10-847){ref-type="table-fn"}
  Washout time                                                                                                                  
   Long                   83.05                                              71.19                                              54.24
   Short                  61.02[\#](#tfn7-ott-10-847){ref-type="table-fn"}   44.07[\#](#tfn7-ott-10-847){ref-type="table-fn"}   23.73[\#](#tfn7-ott-10-847){ref-type="table-fn"}

**Note:**

*P*\<0.05 of comparison within group.

**Abbreviations:** DFS, disease-free survival; TNM, tumor, node, and metastasis; HGF, hepatocyte growth factor; c-Met, cellular mesenchymal to epithelial transition factor; MVD, microvessel density.

###### 

Multivariate survival analysis with Cox's proportional hazards model of risk factors for the prognosis of HCC patients

  Factor                  Risk     95% CI            Regression coefficient   *P*-value
  ----------------------- -------- ----------------- ------------------------ -----------
  Tumor differentiation   0.219    0.143--0.335      −1.521                   \<0.001
  TNM stage               40.668   14.671--112.735   3.705                    \<0.001
  Tumor size              5.701    2.701--12.036     1.741                    \<0.001
  Tumor number            2.938    1.594--5.416      1.078                    0.001
  Vascular invasion       2.731    1.436--5.195      1.005                    0.002
  HGF expression          0.448    0.220--0.916      −0.802                   0.028
  c-Met expression        4.164    1.562--11.098     1.427                    0.004
  MVD                     1.032    1.000--1.065      0.031                    0.049
  Time to peak            1.094    0.985--1.214      0.09                     0.093
  Peak intensity          1.048    1.001--1.098      0.047                    0.044
  Area under the curve    0.989    0.977--1.001      −0.011                   0.084
  Washout time            0.964    0.926--1.003      −0.037                   0.073

**Abbreviations:** TNM, tumor, node, and metastasis; HGF, hepatocyte growth factor; c-Met, cellular mesenchymal to epithelial transition factor; MVD, microvessel density; CI, confidence interval.
